Condition: Myotonic Dystrophy Type 1 (DM1) · DM1 · Myotonic Dystrophy · Sponsor: Dyne Therapeutics
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
This description comes directly from the study's public registry record.
Dyne Clinical Trials · +1-781-317-1919 · clinicaltrials@dyne-tx.com
Always discuss trial participation with your own doctor first.
| UCSD - Altman Clinical and Translational Research Institute | La Jolla, California, United States | Recruiting |
| Rare Disease Research, LLC | Atlanta, Georgia, United States | Recruiting |
| IU Health Neuroscience Center | Indianapolis, Indiana, United States | Recruiting |
| Roy Blunt NextGen Precision Health Institute | Columbia, Missouri, United States | Recruiting |
| Rare Disease Research, LLC | Hillsborough, North Carolina, United States | Recruiting |
| The University of Texas Health Science Center at San Antonio | San Antonio, Texas, United States | Recruiting |
| Virginia Commonwealth University - Biotech One | Richmond, Virginia, United States | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Rigshospitalet, (Neuromuscular Clinic and Research Unit, Department 8077) | Copenhagen, Denmark | Recruiting |
| CHU de Nantes - Hôtel-Dieu | Nantes, France | Recruiting |
| Pitié-Salpêtrière Hospital | Paris, France | Recruiting |
| CHU de Toulouse - Hôpital Pierre-Paul Riquet | Toulouse, France | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07486934